Provided by Tiger Trade Technology Pte. Ltd.

ETF & Stock Investment

2,095.04
-1.9465-0.09%
Number of Gainers:444
Number of Losers:560
Number of Flat:17
PE:- -
High:2,100.64
Open:2,096.97
Low:2,093.04
Close:2,096.93
Volume:2.40B
Turnover:324.16B
Market Cap:97.45T
Float Cap:91.22T

Loading ...

Amazon's Ring to Debut $249 Smart Lock

Dow Jones
·
Oct 07

Wells Fargo Faces US Regulator Probe Over Programs to Boost Black Homeownership, Wall Street Journal Reports

MT Newswires Live
·
Oct 07

Everpure Stock Rides 10-Day Winning Streak. What's Driving the Rally.

Dow Jones
·
Oct 07

Bearish options flow identified in Adobe with shares down 2.29%

TIPRANKS
·
Oct 07

Evercore ISI Adjusts Price Target on Arista Networks to $250 From $200

MT Newswires Live
·
Oct 07

Disney+ to Stream 2027 Super Bowl

Dow Jones
·
Oct 07

IEA Says Members Back 'Prioritization' of Diesel Stock Release

Dow Jones
·
Oct 07

Exclusive-FTC Case Could Lead to Penalties of $500 Million or More, Person Says

THOMSON REUTERS
·
Oct 07

Stocks are Riding High, Bonds are Wild-Who Wins in the End?

Dow Jones
·
Oct 07

Abigail P. Johnson Reports 12.6% Passive Stake in Skyworks Solutions as of September 30 - SEC Filing

THOMSON REUTERS
·
Oct 07

Skydance to combine gaming divisions of Paramount and Warner Bros., Variety says

TIPRANKS
·
Oct 07

Disney+ to Live Stream the Upcoming Super Bowl

Deep News
·
Oct 07

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

TIPRANKS
·
Oct 07

Waters Corp Price Target Raised to $500.00/Share from $460.00 by Barclays

Dow Jones
·
Oct 07

FDA Approves Novartis Rhapsido for Symptomatic Dermographism in Adults

Reuters
·
Oct 07

AI Will Help Shape to Future of Video-Game Development

Dow Jones
·
Oct 07

SIH Partners Cuts Solvay Stake Below 3% Disclosure Threshold

Reuters
·
Oct 07

Novo Nordisk call volume above normal and directionally bullish

TIPRANKS
·
Oct 07

Sodexo Reports 147,454,887 Issued Shares, 216,684,309 Actual Voting Rights as of Sept. 30, 2026

Reuters
·
Oct 07

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

GlobeNewswire
·
Oct 07